JCB, Volume 12, Number 3, 2006 Editorial Vol.12 No. 3 (2006) Editorial: Finding the Holy Grail in a grain of rice Henry I Miller   Article Vol.12 No. 3 (2006) Pitfalls of valuation in biotech Ralph Villiger Biotech companies face the need for valuation at various stages: fund raising, licence contracts, initial public offerings and mergers and acquisitions. The authors exp Article Vol.12 No. 3 (2006) The SEC's enforcement programme on biotechnology's communications with the investment community Arthur S Gabinet The proliferation of biotechnology start-up companies has led to increased scrutiny by the regulators of the securities markets. The author, a former head of a field of Article Vol.12 No. 3 (2006) Commercial biotechnology in Latin America: Current opportunities and challenges Fernando Quezada The unparalleled growth of commercial biotechnology in the USA and Europe during the past two decades has also been marked by its steady development in Latin America. B Article Vol.12 No. 3 (2006) Research collaboration and development of intellectual property with the University of Southampton in the field of asthma and COPD Stephen Holgate The University of Southampton, one of the UK's top ten research universities, has an active enterprise agenda encompassing commercial licensing, spin-out creation, comm Article Vol.12 No. 3 (2006) Bioethical concerns in Japanese biotechnology companies Makina Kato Analysis of responses from a 2003 survey of 304 Japanese biotechnology companies found that 93 per cent responded that they had never had a bioethical problem related t Article Vol.12 No. 3 (2006) Spin-out fever: Spinning out a University of Oxford company and comments on the process in other universities Bruce Savage University spin-out companies are increasing seen as a favoured route for commercialisation of university intellectual property. There has been criticism in the Lambert Article Vol.12 No. 3 (2006) Winning the game: Public funds for biotech companies Michael Gollin This is a transcript from a session held at the Biotechnology Industry Organization 2005 Annual International Convention held in Philadelphia from 19th to 22nd June, 20 Article Vol.12 No. 3 (2006) Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case Emma Gutiérrez de Mesa Vázquez The paper studies strategic alliances signed between traditional pharmaceutical companies (TPCs) and new biotechnology firms (NBFs) in Spain, on the initial basis that Article Vol.12 No. 3 (2006) Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010 Clare A C Churchill Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strate Legal and Regulatory Updates Vol.12 No. 3 (2006) US and EU legal and regulatory update John Wilkinson The Advocate-General of the European Court of Justice (ECJ) has delivered an important opinion that, if adopted by the judges of the court, would mean an extension in t
